Navigation Links
Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Date:4/16/2012

possible."

The IB1001 BLA filing includes a comprehensive set of pharmacokinetics safety, and efficacy data from a Phase 3 clinical trial in people affected by hemophilia B.  A surgery substudy was also included.

John Taylor, Co-Founder and Chairman of Inspiration, stated, "With sons affected by hemophilia B, Inspiration co-founder Scott Martin and I are acutely aware of the impact of limited treatment options on families. We believe more choice can help us achieve our mission to broaden access to care—increasing the supply of products, driving healthy competition, and supporting prophylaxis, which is rapidly becoming the standard of care in hemophilia. We believe that the approval of IB1001 will be the first step in our journey to make broader access to care a reality for thousands of individuals with hemophilia."

About IB1001IB1001 is an intravenous rFIX product being developed for the treatment and prevention of bleeding in individuals with hemophilia B.  IB1001 has completed pivotal Phase 3 clinical studies that support the filling of the BLA, conducted at study sites in the U.S., Europe and India.

To date, IB1001 has been well tolerated by patients and pharmacokinetic (PK) analyses have demonstrated non-inferiority to the one approved rFIX product currently marketed for the treatment of hemophilia B.  Confirmatory PK studies reported at the 53rd Annual Meeting of the American Society of Hematology showed no evidence of development of inhibitors during treatment periods ranging from 4 to 18 months.

Results recently presented at the 5th Annual Congress of the European Association for Haemophilia and Allied Disorders demonstrated that IB1001 provided effective surgical hemostasis in study participants with hemophilia B undergoing major surgical procedures.

About Inspiration BiopharmaceuticalsInspiration Biopharmaceuticals is exclusively dedicated to developing treatments for hemophilia, with a
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Using magnetic toys as inspiration, researchers tease out structures of self-assembled clusters
3. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
4. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
7. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
8. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
9. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
10. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
11. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014 -- A novel combination of microscopy and data ... Oak Ridge National Laboratory an unprecedented look at the ... and electrochemical properties. , The research team led ... surface of a perovskite manganite, a complex material that ... to understand surface behavior could benefit researchers who are ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... 24, 2014  Now available is a stem cell ... Regenerative Therapies , located in Guadalajara, Mexico ... people a new health option: stem cell therapies ... countless patients suffer from joint and muscle injuries due ... tears, torn rotator cuff, tennis elbow, and knee injuries. ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... WAYNE, Pa., May 15 Escalon Medical Corp.,(Nasdaq: ... quarter and,nine months ended March 31, 2008., For ... 18% to,$8,139,000 compared with $6,900,000 reported in the same ... sales in each of the,Company,s business units., Net ...
... biotechnology company that is focused on the development of,autologous (patient-derived) ... heart damage, today announced financial results for,the quarter ended March ... 19, 2008, the Company completed its initial public offering ... of approximately $5.8 million. The net ...
... Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends strategies, ... Inc. and,the International Expert Wound Care Advisory Panel ... Improve Pressure,Ulcer Prevention and Treatment: Implications of the ...
Cached Biology Technology:Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8Bioheart, Inc. Announces Financial Results for First Quarter 2008 2Bioheart, Inc. Announces Financial Results for First Quarter 2008 3Bioheart, Inc. Announces Financial Results for First Quarter 2008 4Bioheart, Inc. Announces Financial Results for First Quarter 2008 5Bioheart, Inc. Announces Financial Results for First Quarter 2008 6Bioheart, Inc. Announces Financial Results for First Quarter 2008 7International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
(Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... acne (Propionibacterium acnes) will be the topic of the Denver ... University. As well as acne, this bacterium is responsible for ... diagnosis. Why are we not more aware of this versatile ... and boost the immune system: , Probiotics can ...
... Most college students in the United States do ... an essential skill in understanding the causes and ... the January issue of BioScience . The ... from Michigan State University, calls for a new way ...
... Scientists at Rothamsted Research, United Kingdom, in collaboration with ... Areas (ICARDA), Syria have developed a method of accounting ... trend refers to the variations in crop yield and ... trial. Usually plant breeders will grow several replicate ...
Cached Biology News:Probiotics, prebiotics and biofuel-producing bacteria 2College students lack scientific literacy, study finds 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Protein size: 325 Accession ... using peptide based assay: 1:1562500 ... 1.0g/ml in 5% skim milk / ... should be diluted in 1: 50,000 - ...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Active GST Protein...
Biology Products: